The ongoing clinical trials in other kidney diseases, beyond diabetic nephropathy, and the design of additional novel trials including a larger number of patients and longer outcome duration would contribute to set up Nrf2 as one of the most promising therapeutic targets for kidney disease, an area with scarce number of novel medications. The gene discussed is NFE2L2; the disease is diabetic kidney disease.